Medical device maker AtriCure (NASDAQ:ATRC) is looking to obtain regulatory clearance to use its AtriClip heart device on stroke patients. The Cincinnati-area company is planning next year to begin a ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
WEST CHESTER, Ohio — AtriCure has received approval in Europe for its AtriClip, a device that protects against clotting during certain heart procedures. Europe’s granting of the CE Mark for the ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received ...
Shares of West Chester, OH-based AtriCure soared on news that the FDA approved the company's AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System, a device which blocks blood clots during ...
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results